TXMD
TherapeuticsMD, Inc. NASDAQ Listed May 9, 2007$2.01
+0.50%
vs $2.00
Mkt Cap $23.3M
52w Low $1.04
56.1% of range
52w High $2.77
50d MA $2.06
200d MA $1.84
P/E (TTM)
130.5x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.2x
ROE
-2.1%
P/FCF
9.5x
RSI (14)
51.90
ATR (14)
$0.15
Beta
0.56
50d MA
$2.06
200d MA
$1.84
Avg Volume
50.3K
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
951 Yamato Road · Boca Raton, FL 33431 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -6.12 | -0.05 | +99.1% | 1.99 | -4.5% | +1.5% | -1.0% | +0.0% | +10.0% | -8.2% | — |
| Nov 12, 2025 | AMC | — | 0.01 | — | 1.68 | +1.2% | -3.6% | +21.0% | -22.4% | +1.3% | +7.1% | — |
| Aug 12, 2025 | AMC | — | 0.05 | — | 1.11 | -0.9% | +4.5% | -0.9% | +1.7% | -2.6% | +1.8% | — |
| May 13, 2025 | AMC | — | -0.06 | — | 1.52 | -0.7% | -3.9% | +0.0% | +2.7% | -1.3% | +0.7% | — |
| Mar 27, 2025 | AMC | 0.04 | 0.02 | -45.2% | 1.05 | -2.9% | -6.5% | -5.8% | +5.9% | +2.0% | -3.0% | — |
| Nov 12, 2024 | AMC | 0.04 | -0.05 | -225.0% | 1.50 | -0.7% | +0.0% | -2.7% | -4.1% | -7.9% | +0.8% | — |
| Aug 12, 2024 | AMC | 0.03 | -0.09 | -400.0% | 1.67 | +4.8% | +2.4% | -4.7% | -1.2% | +3.1% | -0.6% | — |
| May 10, 2024 | AMC | 0.03 | -0.07 | -333.3% | 2.03 | -0.5% | +2.5% | -1.9% | +2.5% | +1.4% | +4.7% | — |
| Mar 29, 2024 | AMC | -0.13 | -0.08 | +38.5% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -0.15 | -0.13 | +13.3% | 2.01 | +0.0% | +17.4% | -0.4% | -3.4% | +28.6% | -4.6% | — |
| Aug 14, 2023 | AMC | -0.07 | -0.24 | -242.9% | 3.85 | -0.3% | -0.3% | -4.7% | -0.3% | +2.7% | +1.9% | — |
| May 15, 2023 | AMC | 0.06 | -0.24 | -500.0% | 4.39 | +5.7% | +0.2% | -4.8% | +1.2% | +1.9% | -0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $3.66 | $3.50 | -4.4% | -0.3% | +2.7% | +1.9% | +0.5% | +2.3% |
| Jun 7 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $9.97 | $9.89 | -0.8% | -0.4% | -0.1% | -0.1% | +0.4% | +0.2% |
| May 6 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $8.50 | $9.00 | +5.9% | -11.8% | -35.5% | -5.0% | -24.8% | -13.9% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.50 | $14.50 | +0.0% | +0.0% | -6.9% | +22.2% | +12.1% | +5.4% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.00 | $32.50 | -1.5% | -4.5% | -3.2% | -3.3% | -3.4% | +1.8% |
| Aug 7 | Jefferies | Downgrade | Hold → Underperform | — | $80.50 | $84.00 | +4.3% | +3.7% | -6.0% | -1.3% | +2.6% | -2.5% |
| May 19 | JP Morgan | Downgrade | Overweight → Neutral | — | $59.50 | $58.00 | -2.5% | -6.7% | +1.8% | +5.3% | +5.0% | -2.4% |
| Apr 16 | Stifel | Maintains | Buy → Buy | — | $43.50 | $45.00 | +3.4% | +8.0% | +1.1% | +0.0% | -4.2% | +0.0% |
| Feb 21 | H.C. Wainwright | Maintains | Buy → Buy | — | $107.50 | $107.50 | +0.0% | -4.2% | -7.8% | -2.6% | -3.8% | -6.7% |
| Aug 14 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $258.00 | $262.50 | +1.7% | +6.4% | -0.9% | +2.0% | -2.9% | +1.5% |
| Jul 11 | Oppenheimer | Upgrade | Perform → Outperform | — | $240.00 | $261.50 | +9.0% | +4.0% | +0.2% | +11.4% | +1.1% | -6.6% |
| May 9 | Oppenheimer | Downgrade | Outperform → Perform | — | $209.00 | $198.00 | -5.3% | +4.5% | -2.7% | +0.9% | +3.7% | +1.3% |
| Dec 6 | Stifel | Maintains | Buy → Buy | — | $308.50 | $365.50 | +18.5% | +12.8% | -4.3% | -7.5% | +0.0% | -4.5% |
| Mar 4 | Stifel | Maintains | Buy → Buy | — | $337.50 | $352.00 | +4.3% | +4.6% | +5.2% | +5.0% | -0.3% | +0.4% |
No insider trades available.
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
Texmed International's late annual report filing signals potential regulatory compliance issues and financial uncertainty, which could trigger delisting risk and erode investor confidence in management's operational competence.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
TherapeuticsMD's royalty-based business model provides predictable cash flows independent of R&D execution, making it attractive for income-focused investors seeking stability over growth volatility.
Mar 30
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Clearline Capital Lp | 635,222 | $1M | — | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 353,697 | $714K | New | Mar 2026 |
| 3 | Tejara Capital Ltd | 345,852 | $699K | Reduced | Mar 2026 |
| 4 | Adar1 Capital Management, Llc | 209,210 | $423K | New | Mar 2026 |
| 5 | Morgan Stanley | 258,434 | $421K | Reduced | Dec 2025 |
| 6 | Renaissance Technologies Llc | 146,200 | $295K | Added | Mar 2026 |
| 7 | Citadel Advisors Llc | 68,314 | $138K | Added | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 21,220 | $43K | Reduced | Mar 2026 |
| 9 | Northern Trust Corp | 16,093 | $33K | Reduced | Mar 2026 |
| 10 | Cygnus Capital Advisors, Llc | 9,069 | $18K | New | Mar 2026 |
| 11 | Eversource Wealth Advisors, Llc | 142 | $1K | Added | Mar 2026 |
| 12 | Smartleaf Asset Management Llc | 601 | $1K | — | Mar 2026 |
| 13 | Ubs Group Ag | 331 | $669 | Reduced | Mar 2026 |
| 14 | Jpmorgan Chase & Co | 293 | $583 | — | Mar 2026 |
| 15 | Bnp Paribas Financial Markets | 226 | $457 | — | Mar 2026 |
| 16 | Us Bancorp \de\ | 246 | $401 | — | Dec 2025 |
| 17 | Wells Fargo & Company/mn | 115 | $232 | New | Mar 2026 |
| 18 | Fmr Llc | 51 | $103 | Reduced | Mar 2026 |
| 19 | Steward Partners Investment Advisory, Llc | 35 | $71 | — | Mar 2026 |
| 20 | Activest Wealth Management | 40 | $65 | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 67,220 | $152K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 15,320 | $35K | Feb 2026 |
| 3 | Ultra-Small Company Market Fund | 17,000 | $34K | Mar 2026 |
| 4 | Fidelity Total Market Index Fund | 14,835 | $34K | Feb 2026 |
| 5 | Fidelity OTC Portfolio | 6,770 | $15K | Jan 2026 |
| 6 | The Gabelli ABC Fund | 3,600 | $7K | Mar 2026 |
| 7 | Enterprise Mergers and Acquisitions Fund | 1,000 | $2K | Mar 2026 |
| 8 | Fidelity OTC K6 Portfolio | 499 | $1K | Jan 2026 |
| 9 | Guggenheim Active Allocation Fund | 46 | $104 | Feb 2026 |
Valuation
Market Cap
$23.3M
Enterprise Value
$15.8M
P/E (TTM)
130.52x
Forward P/E
11.82x
PEG Ratio
0.45x
P/B
0.87x
P/S
6.94x
P/FCF
9.48x
EV/EBITDA
—
Shares Out
11.6M
Financials (TTM)
Revenue
$3.4M
Net Income
$179K
EBITDA
-$3.7M
Free Cash Flow
$2.5M
Op Cash Flow
$2.5M
EPS Basic
$-0.05
EPS Diluted
$0.02
EPS Forward
$0.17
Gross Margin
90.3%
Op Margin
-111.7%
Net Margin
5.3%
Balance Sheet
Total Assets
$37.7M
Total Liab.
$10.8M
Total Equity
$26.9M
Cash
$7.5M
LT Debt
$0
Book Value/Sh
$2.32
Debt/Equity
0.19x
Current Ratio
3.02
Quick Ratio
3.02
Returns & Growth
ROE
-2.1%
ROA
-1.5%
ROIC
-11.2%
Rev Growth YoY
+71.6%
EPS Growth YoY
+74.1%
Price Returns
2W
+7.5%
1M
+4.9%
3M
-5.3%
6M
+25.9%
12M
+46.6%
Technicals
52W High
$2.77
52W Low
$1.04
50d MA
$2.06
200d MA
$1.84
RSI (14)
51.90
ATR (14)
$0.15
Beta
0.56
Avg Volume
50K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 6:15am
· Source: financialmodelingprep.com